MarkChristopherMarkowskiMD

Oncology • Washington, DC

Instructor, Medicine, Johns Hopkins University School of Medicine

Join to view full profile

Are you Dr. Markowski?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
5255 Loughboro Road Northwest
Washington, DC 20016

Summary

Dr. Mark Markowski, MD is an oncologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Virginia, and Pennsylvania. He is affiliated with Sibley Memorial Hospital, Johns Hopkins Hospital, and Johns Hopkins Bayview Medical Center.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Georgetown University School of MedicineClass of 2009

Certifications & Licensure

VA State Medical License 2022 - 2026
MD State Medical License 2012 - 2025
DC State Medical License 2015 - 2024
PA State Medical License 2020 - 2022
NY State Medical License 2011 - 2013

Clinical Trials

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Start of enrollment: 2018 Sep 10
Active, not recruiting
Phase 2
COMbination of Bipolar Androgen Therapy and Nivolumab Start of enrollment: 2018 Sep 05
Completed
Phase 2
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations Start of enrollment: 2019 Jun 03
Recruiting
Phase 2
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer Start of enrollment: 2019 Oct 01
Withdrawn
Phase 2, Phase 3
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Start of enrollment: 2020 Jan 13
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
Elizabeth U Tran, Eric Royz, Kyra Yamamoto, Samantha Marley, Alexander Song
The Prostate. 2025-01-01
Initial Experience with [Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H Marshall
Journal of Nuclear Medicine. 2024-11-01
1 citations
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, Lia Oliveira, Hao Wang
JAMA Oncology. 2024-10-01

Press Mentions

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
COMBAT-CRPC Points to Potential of Combining BAT, NivolumabMay 6th, 2021
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerDecember 9th, 2020
Join now to see all